Department of Dentistry, Hangang Secred Heart Hospital, College of Medicine, Hallym University 94-195 Youngdeungpo-dong, Youngdeungpo-gu, Seoul 150030, Republic of Korea.
Biomaterials. 2010 May;31(13):3512-9. doi: 10.1016/j.biomaterials.2010.01.075. Epub 2010 Feb 9.
We investigated the ability of recombinant human bone morphogenetic protein-2, produced from Escherichia coli (ErhBMP-2), to form orthotopic and ectopic bone in rat models. BMP-2 was expressed in E. coli and extracted from the inclusion bodies. Critical-sized calvarial defects and subcutaneous pouches were created in rats, and an absorbable collagen sponge (ACS) was loaded with different doses of ErhBMP-2 for implantation. ACS alone and sham surgery controls were also included. Implant sites were evaluated by histological and/or histometric analyses following a 2- or 8-week healing interval. In the calvarial defect model, enhanced bone formation was observed with all doses of ErhBMP-2, while only limited amounts of new bone were found in controls. In the ectopic subcutaneous implant model, bone formation was clearly observed in all animals treated with ErhBMP-2 at 2 weeks. However, at 8 weeks, less new bone formation was detected than at 2 weeks. Nevertheless, the remaining new bone showed an advanced degree of bone remodeling and more maturity than that observed at 2 weeks. These results showed that ErhBMP-2 was osteoinductive under controlled in vivo conditions. Thus, ErhBMP-2 has definite potential as an alternative to rhBMP-2 produced in a eukaryotic system for clinical use.
我们研究了从大肠杆菌(ErhBMP-2)中表达的重组人骨形态发生蛋白-2(rhBMP-2)在大鼠模型中形成原位和异位骨的能力。rhBMP-2 在大肠杆菌中表达并从包涵体中提取。在大鼠中创建了临界大小的颅骨缺损和皮下囊,并将不同剂量的 ErhBMP-2 加载到可吸收胶原海绵(ACS)上进行植入。还包括 ACS 单独和假手术对照。在 2 或 8 周的愈合间隔后,通过组织学和/或组织计量分析评估植入部位。在颅骨缺损模型中,所有剂量的 ErhBMP-2 均观察到增强的骨形成,而对照仅发现有限量的新骨。在异位皮下植入模型中,所有接受 ErhBMP-2 治疗的动物在 2 周时均明显观察到骨形成。然而,在 8 周时,新骨形成的量比 2 周时少。尽管如此,残留的新骨显示出更高程度的骨重塑和成熟度,比 2 周时观察到的更成熟。这些结果表明,ErhBMP-2 在受控的体内条件下具有成骨诱导性。因此,ErhBMP-2 具有作为替代在真核系统中产生的 rhBMP-2 用于临床用途的明确潜力。